Design and Synthesis of New Thiazole Derivatives for Alzheimer’s Disease Therapy as a Potential Cholinesterase Inhibitor; Toxicity Prediction and Molecular Docking Studies and Biological Evaluation
Authors:
- Mesut IşıkMesut Işık
- Gresa Halimi SylaGSGresa Halimi Syla
- Abdüllatif KarakayaAKAbdüllatif Karakaya
- Ulviye Acar ÇevikUÇUlviye Acar Çevik
- Nour El-Huda DaoudNDNour El-Huda Daoud
- Muhammet FıratMFMuhammet Fırat
- Yüksel Öğünç KeçeciYKYüksel Öğünç Keçeci
- Yusuf ÖzkayYÖYusuf Özkay
- Zafer Asım KaplancıklıZKZafer Asım Kaplancıklı
- Şükrü BeydemirŞBŞükrü Beydemir
Open Access
Abstract
In this study, thiazole derivatives 13–23 were synthesized as novel cholinesterase inhibitors. Their structures were elucidated using 1H-NMR, 13C-NMR, and elemental analysis techniques. The binding positions and efficiencies of the designed compounds on the enzyme were investigated through molecular docking studies, and the properties of ADMET were examined using computational methods. Cytotoxicity analyses of the synthesized compounds were performed to screen their inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in vitro. It has been determined that these compounds do not exhibit a significant cytotoxic effect on healthy endothelial cells. Although the compounds showed lower efficacy in AChE inhibition compared to the reference compound tacrine (IC50: 0.136 μM; KI: 0.46 ± 0.01 nM), they exhibited moderate inhibitory effects. Among these, compounds 16 and 23 were found to be the most potent AChE inhibitors, with IC50 values of 36.47 µM and 34.65 µM, and KI values of 22.20 ± 1.23 and 21.10 ± 1.58 µM, respectively, while compounds 15 and 20 were found to be the most potent BChE inhibitors, with IC50 values of 17.76 µM and 16.90 µM, and KI values of 14.10 ± 0.58 and 13.40 ± 0.48 µM, respectively, on other cholinesterases. These tested compounds can be considered potential candidates for further research in the treatment of Alzheimer’s disease (AD).Keywords
Funding Information
- Anadolu University (THD-2026-3611)
This publication has 34 references indexed in Scilit:
- MD Simulations, DFT and Molecular Docking Studies of Schiff Base–Derived Heterocycles as Potent BuChE Inhibitors for Alzheimer's DiseaseChemistrySelect, 2026
- Design, Synthesis, In Silico Absorption, Distribution, Metabolism, and Elimination and Molecular Docking Studies of Thiazole‐Based Furan Derivatives, and Their Biological Evaluation for Alzheimer Disease TherapyChemistryOpen, 2025
- Integrated insight and in silico investigation of hybrid bis-thiazolidinone derivatives along with anti-Alzheimer activity3 Biotech, 2025
- Sulfonamide‐Bearing Pyrazolone Derivatives as Multitarget Therapeutic Agents: Design, Synthesis, Characterization, Biological Evaluation, In Silico ADME/T Profiling and Molecular Docking StudyPharmacology Research & Perspectives, 2025
- Structure‐Based Approaches for the Prediction of Alzheimer's Disease Inhibitors: Comparative Interactions Analysis, Pharmacophore Modeling and Molecular Dynamics SimulationsChemistrySelect, 2024
- Design and Synthesis of Pyrazole Carboxamide Derivatives as Selective Cholinesterase and Carbonic Anhydrase Inhibitors: Molecular Docking and Biological EvaluationChemistry & Biodiversity, 2024
- Structure‐based design of new N‐benzyl‐piperidine derivatives as multitarget‐directed AChE/BuChE inhibitors for Alzheimer's diseaseJournal of Cellular Biochemistry, 2023
- Design, synthesis, biological activities, and evaluation of molecular docking‐dynamics studies of new thiosemicarbazones that may be effective against Alzheimer's diseaseJournal of Molecular Recognition, 2023
- Novel bis-ureido-substituted sulfaguanidines and sulfisoxazoles as carbonic anhydrase and acetylcholinesterase inhibitorsMolecular Diversity, 2022
- A new and rapid colorimetric determination of acetylcholinesterase activityBiochemical Pharmacology, 1961